

Bazylevych, Bazilevych, Bazilevich, Basylevych

List of Publications by Year in Descending Order

Source:

<https://exaly.com/author-pdf/25466/bazylevych-bazilevych-bazilevich-basylevych-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

21,336
citations

21
h-index

31
g-index

31
ext. papers

25,298
ext. citations

27.2
avg, IF

5.83
L-index

#	Paper	IF	Citations
27	A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps. <i>Nutrition Journal</i> , 2021 , 20, 90	4.3	1
26	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
25	Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. <i>Diabetes Care</i> , 2020 , 43, 726-733	14.6	24
24	Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey. <i>Atherosclerosis</i> , 2020 , 313, 35-42	3.1	3
23	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320908698	3.9	25
22	The effect of therapy with olmesartan or telmisartan in patients with arterial hypertension combined with obesity. <i>Wiadomości Lekarskie</i> , 2020 , 73, 321-324	0.3	1
21	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019 , 285, 135-146	3.1	106
20	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
19	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
18	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
17	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. <i>Journal of Hypertension</i> , 2016 , 34, 139-48	1.9	8
16	Long-term use of ticagrelor in patients with prior myocardial infarction. <i>New England Journal of Medicine</i> , 2015 , 372, 1791-800	59.2	1193
15	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
14	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 1091-9	59.2	315
13	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858
12	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2013 , 369, 2093-104	59.2	3215
11	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology, The</i> , 2012 , 11, 503-11	24.1	212

10	Tiotropium versus salmeterol for the prevention of exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011 , 364, 1093-1103	59.2	499
9	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , 2011 , 364, 11-21	59.2	1890
8	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
7	Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. <i>Journal of Rheumatology</i> , 2011 , 38, 1875-83 ^{4.1}	2	
6	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010 , 376, 875-85	40	1646
5	Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009 , 30, 540-8	9.5	241
4	Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2009 , 11, 611-22	6.7	249
3	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	40	775
2	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
1	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). <i>European Heart Journal</i> , 2005 , 26, 215-25	9.5	1076